Leading Industrial Hemp Biosciences Company Sets Sites on Furthering Ophthalmology-Focused Cannabinoid Research and Development, Expands R&D Portfolio With Cannabinoid-Based Ophthalmological Products
NEW YORK, Jan. 20, 2015 (GLOBE NEWSWIRE) — AXIM Biotechnologies (OTC:AXIM) is actively recruiting top minds and experts in medicine. The Company is pleased to announce that Murad A. Sunalp M.D., B.M., B. Ch. MBA has joined AXIM Biotechnologies’ Board of Advisors. Dr. Sunalp brings extensive knowledge of ophthalmology to the Company’s industrial hemp-based pharmaceutical research and development projects.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=30157
“We are delighted to inform the public and our shareholders that Dr. Sunalp has joined our Medical Advisory Board,” states George E. Anastassov, MD, DDS, MBA and Chief Executive Officer for AXIM Biotechnologies. “Murad is well respected nationally and internationally as an ophthalmologist, entrepreneur and contributor to charitable vision surgeries worldwide. Dr. Sunalp trained at the most prestigious institutions including Oxford and Stanford. He brings with him over 30 years of clinical and academic wealth of knowledge.”
Anastassov continues, “Some of the products in our R&D pipeline are cannabinoid-based ophthalmological preparations. We feel that the contributions of Dr. Sunalp in these endeavors will be paramount to furthering our advances in industrial hemp-based pharmaceutical product development.”
Dr. Murad A. Sunalp offers extensive expertise on diseases of the eye and has performed more than 20,000 cataract surgeries and over 5,000 LASIK procedures in his more than three decades of clinical practice. His specialties include anterior segment, intraocular lens and phacoemulsification cataract surgery, LASIK and Excimer refractive surgery, VISX CustomVue individualized laser vision correction, as well as glaucoma, PRK and CK procedures.
Throughout his 37-year career, Dr. Sunalp has been involved in more than 65 ophthalmologic publications and studies along with numerous charitable surgeries in four countries.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@AXIMBiotech.com or call 858-380-5478.
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227